| Autor: |
Delavallée L; University Paris 13, PRES Paris Cité Sorbonne, Bobigny, France. laure.delavallee@upmc.fr, Duvallet E, Semerano L, Assier E, Boissier MC |
| Jazyk: |
angličtina |
| Zdroj: |
Swiss medical weekly [Swiss Med Wkly] 2010 Nov 01; Vol. 140, pp. w13108. Date of Electronic Publication: 2010 Nov 01 (Print Publication: 2010). |
| DOI: |
10.4414/smw.2010.13108 |
| Abstrakt: |
The concept of therapeutic vaccination represents a novel strategy of active immunotherapy that can be applied to autoimmune disease. The principle is to design molecules which can trigger an immune response, targeting a cytokine that is pathogenic and over-expressed in a given disease. The mostly available vaccines are an application of vaccination using either the self-protein coupled to a carrier (type I A), or a modified form of the protein engineered to include neo-epitopes (type I B). These approaches have been developed in models of several autoimmune diseases, mainly in TNFα-dependent diseases such as rheumatoid arthritis and Crohn's disease, but also in systemic lupus erythematosus, multiple sclerosis and myasthenia gravis. Clinical trials are in progress in rheumatoid arthritis, Crohn's disease and diabetes. The benefit/risk ratio of anti-cytokine vaccination is currently under study to further develop the vaccination strategies. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
